🔗 Share this article

The first new treatments for gonorrhoea in decades are being described as a "significant breakthrough" in the effort against drug-resistant strains of the infection, according to scientists.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating globally, with data suggesting more than 82 million new cases annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which includes Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely development in the reality of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The World Health Organization has listed it as a "high-priority threat". Ongoing monitoring found that the effectiveness of key first-line drugs like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Recent Drugs Secure Authorization

One new antibiotic, also known as a brand name, was authorized by the American regulatory agency in mid-December for combating gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This medication, which is employed against urinary tract infections, was proven in research to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the therapy of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Research Study Data and Global Access

According to results released by a major medical journal, the new drug cured over nine in ten of genital gonorrhoea infections. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The study included hundreds of volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its unique model, the non-profit has the ability to make available and distribute the drug in many regions with limited resources.

Doctors treating patients have shared hope. Access to a easy-to-administer therapy of this kind is hailed as a "game-changer" for managing the epidemic. This is considered crucial to alleviate the strain of the illness for individuals and to prevent the spread of highly drug-resistant gonorrhoea worldwide.